Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

SEL24 / MEN1703 in Patients With Acute Myeloid Leukemia

The purpose of the clinical trial is to identify the highest dose of SEL24 / MEN1703 drug with acceptable safety profile and that can be used in patients with Acute Myeloid Leukemia.
Leukemia
Phase I/II
Adults
Mol. targeted/Immunotherapy/Biologics
SEL24, SEL24/MEN1703
Strickland, Stephen
National
Vanderbilt University
05-03-2017
A Phase I/II Study of SEL24 in Patients with Acute Myeloid Leukemia
Treatment
VICCHEM16123
NCT03008187

Eligibility

18 Years
BOTH
NO
Inclusion Criteria:

patients with diagnosis of Acute Myeloid Leukemia

patients has no standard therapeutic options (newly diagnosed Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia ans Primary Refractory Acute Myeloid Leukemia).



Exclusion Criteria:

anti-cancer treatments (including cytotoxic chemotherapy, radiotherapy, hormonal therapy, biologic, immunotherapy or investigational drugs) received within 14 days or 5 half-lives for targeted therapies (whichever is shorter) before first dose of study drug (to be supplemented)

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: